The content on this site is intended for healthcare professionals only
Prof Nicholas Short speaks to ecancer about a study he presented at the ASH 2021 meeting into the use of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukaemia.
He reports that the triplet combination showed a response rate of 69% in the relapsed/refractory population and 100% in the front-line cohort.
Prof Short explains that the study continues to enrol patients and his hope is, if the data holds up, that this could be used more broadly out of clinical trials.
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
EHA 2024: Multiple myeloma roundup
More effective treatment options required for patients with MM post lenalidomide exposure
Manageable safety profile with early efficacy of Tec-DR in NDMM
Multiple myeloma in a resource constrained setting
Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
